“A category 1 designation from the NCCN is not just a footnote change — it’s a signal flare,” said Dr. Aaron Gerds, MD, a hematologist,

In the clinic with a young MPN patient  A young adult sits across from Dr. Linda Resar, hands clasped, voice unsteady. The diagnosis is a mouthful —

Inside the Orlando Convention Center, a room as vast as an airline hangar was bathed in green light from numerous two-story-high screens. Thousands of hematology researchers filled

MPN Research Foundation: A legacy of impact Sources Kralovics, R., et al. (2002). Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect

Few scientists have a clearer view of where myeloproliferative neoplasm (MPN) research is headed than Dr. Ann Mullally, MD. As a physician-scientist, Division Chief of

What GLP-1 drugs reveal about MPNs, inflammation, and cancer risk A surprising link between inflammation, clonal blood stem cells, and a blockbuster drug opens new